Product Name: Abarelix
CAS No: 183552-38-7
Purity: 95%
Molar Mass: 1416.06
Chemical Formula: C72H95ClN14O14
Synonyms: R3827; PPI 149
Storage: Store at -20℃
Sequence: XXXSYNLXPA
Target: gonadotrophin-releasing hormone
Application: Abarelix (CAS: 183552-38-7) is a synthetic peptide antagonist of gonadotropin-releasing hormone (GnRH) receptors used in the treatment of advanced prostate cancer. It functions by competitively binding to GnRH receptors in the pituitary gland, thereby inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This blockade leads to a reduction in testosterone production, which is crucial for the growth and progression of prostate cancer cells. Abarelix is particularly effective in patients with hormone-sensitive prostate cancer, offering a rapid and sustained suppression of testosterone levels without the initial testosterone surge associated with GnRH agonists. In pharmaceutical chemistry, abarelix’s targeted antagonism of GnRH receptors represents a significant advancement in the management of advanced prostate cancer, providing a specific and effective therapeutic option for patients with this aggressive malignancy. Its application underscores its importance in oncology and improving outcomes for individuals with hormone-sensitive prostate cancer. Additionally, ongoing research explores abarelix’s potential in combination therapies and its role in other hormone-related conditions, highlighting its versatility in endocrine therapeutics.
Reference:
